Autophosphorylation of Activation Loop Tyrosines Regulates Signaling by the TRK Nerve Growth Factor Receptor*

(Received for publication, October 9, 1996, and in revised form, January 24, 1997)

Matthew E. Cunningham Dagger , Robert M. Stephens §, David R. Kaplan § and Lloyd A. Greene Dagger par

From the Dagger  Department of Pathology and Center of Neurobiology and Behavior, College of Physicians and Surgeons, Columbia University, New York, New York 10032, the § ABL-Basic Research Program, Frederick, Maryland 21702, and the  Montreal Neurological Institute, McGill University, Montreal, Quebec H3A 2B4, Canada

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

Many receptor tyrosine kinases possess an "activation loop" containing three similarly placed tyrosine autophosphorylation sites. To examine their roles in the TRK NGF receptor, these residues (Tyr-670, Tyr-674, and Tyr-675) were mutated singly and in all combinations to phenylalanine and stably expressed in Trk-deficient PC12nnr5 cells. All mutant receptors showed significantly diminished nerve growth factor (NGF)-stimulated autophosphorylation, indicating impaired catalytic activity. NGF-induced neurite outgrowth exhibited dose-responsive behavior when transfectants were compared by relative receptor expression and exhibited a functional hierarchy: wild type > Y670F >=  Y674F >>  Y675F >=  YY670/674FF = YY670/675FF >>  YY674/675FF > YYY670/674/675FFF. NGF-induced tyrosine phosphorylation of Shc, ERKs, and SNT and immediate early gene inductions generally paralleled neurogenic potential. However, activation of phosphatidylinositol 3'-kinase and tyrosine phosphorylation of phospholipase Cgamma -1 was essentially abolished. The latter effect appears due to selective inability of the mutated TRKs to autophosphorylate the tyrosine residue (Tyr-785) required for binding phospholipase Cgamma -1 and indicates that the "activation loop" tyrosines participate in NGF-dependent changes in receptor conformation. Our findings stress the importance that expression levels play in assessing the consequences of receptor mutations and that all three activation loop tyrosines have roles regulating both overall and specific NGF-mediated signaling through TRK.


INTRODUCTION

For many growth factors, ligand-mediated activation of receptor tyrosine kinases (RTKs)1 is the first essential step leading to biological responses (1, 2). Nerve growth factor (NGF) and other neurotrophins bind to and activate particular members of the Trk receptor tyrosine kinase family (3, 4); NGF binds to and activates TRKA (5, 6). The pheochromocytoma-derived PC12 cell line (7) has been highly useful for studying NGF signal transduction and its molecular mechanisms of action. PC12 cells respond to NGF by undergoing neuronal differentiation, survival in serum-free medium, cell hypertrophy, and regulation of numerous biochemical markers (8). NGF induces rapid tyrosine phosphorylation of TrkA and consequent phosphorylation and activation of signal transduction components including Shc, extracellular signal-regulated kinases (ERKs), phosphatidylinositol 3'-kinase (PI3'K), phospholipase C gamma -1 (PLCgamma -1), and SNT (9). Activation of these signal transduction molecules culminates in downstream signaling events, including the induction of immediate early and late genes (10, 11).

As with other ligands and their cognate RTKs (1, 2), NGF appears to initiate signaling through TrkA by the sequential steps of dimerization, trans-autophosphorylation on tyrosine residues and kinase activation, followed by binding and tyrosine phosphorylation of substrates (9, 12, 13). In vitro studies indicate that TRKA autophosphorylates at tyrosines 490, 670, 674, 675, and 785 (14, 15). To analyze the significance of these phosphorylation events in NGF signaling, we have introduced TRKA receptors modified at these residues into the mutant PC12 cell line, PC12nnr5, that expresses no detectable endogenous TrkA (16, 17). This analysis reveals that phosphotyrosines 490 and 785 are required for binding and activation of Shc and PLC gamma -1, respectively (14, 15, 18). The three remaining tyrosine autophosphorylation sites, Tyr-670, Tyr-674, and Tyr-675, are contained within the kinase domain of the receptor and are within a sequence motif that is not typical for an SH2 protein binding site (19) or for other protein-protein interactions (20, 21). Comparison of this sequence motif with other protein kinases reveals homology with a number of RTKs (22-27). Studies carried out largely with wild type and mutated insulin, IGF and c-Met/HGF receptors indicate that these sites are important for initial ligand-induced autophosphorylation and that they are required for efficient signal transduction and promotion of biological responses (28-36).

A physical model that begins to account for the roles of the three conserved kinase domain tyrosines is provided by the crystal structure of the non-phosphorylated insulin receptor kinase domain (37). This structure indicates that the three kinase domain tyrosines lie near the catalytic core of the kinase within an "activation loop" that prevents binding of ATP as well as physical approximation of the amino and carboxyl lobes of the kinase domain. The activation loop appears to be stabilized in this inhibitory conformation by interactions of Tyr-1162 (the homologue of Tyr-674 in TRK) with residues near the catalytic core of the kinase. This interaction also inhibits basal kinase activity by acting as a pseudosubstrate. Furthermore, it was suggested that ligand-promoted phosphorylation of activation loop tyrosines induces movement of the loop away from the catalytic core to permit efficient kinase activation.

Although studies on activation loop tyrosines in several systems collectively suggest that they function to regulate RTK activation, the roles of individual tyrosines are unclear and are subject to some inconsistency within the literature (29, 38-45). For example, tyrosine to phenylalanine mutation in the insulin receptor at the residue equivalent to TRK Tyr-670 in one case was reported to have no effect on in vitro kinase activity (35), whereas in several other studies the same mutation was reported to reduce in vitro kinase activity by approximately 80% (39) or more (41). It also appears that there may be differences between the roles of each of the activation loop tyrosines in the various receptors (34, 38, 39, 44). Moreover, past studies have indicated that mutation of individual activation loop tyrosines may selectively abolish some receptor-mediated biological responses while sparing others, although the mechanistic basis for these observations is unknown. In the present study, we have examined the activation loop tyrosines in the TRKA receptor with respect to their roles in regulating signaling and biological responses to NGF. To achieve this, we mutated the tyrosines singly and in all combinations and have stably expressed receptors containing these mutations in PC12nnr5 cells at various levels of expression. Our findings are consistent with a major role for tyrosines 670, 674, and 675, not only in regulating overall catalytic activity of the receptor but also in governing site-specific receptor autophosphorylation.


MATERIALS AND METHODS

Construction of TRKA Mutants and Production of pLNC(TRKA)s

TRKA mutants were constructed using single strand mutagenesis (Bio-Rad). Briefly, full-length TRKA was used to generate antisense template, and sense oligonucleotides were used to introduce the point mutations. For double and triple mutations, oligonucleotides spanning all mutated sites were used. In the multiple site mutation constructs, restriction site cassettes containing each zone mutation (e.g. Y490F, Y785F etc.) were shuttled between the autophosphorylation loop backbones and then sequenced for confirmation. The mutant TRKs were then cloned into the pLNCX5 retroviral expression vector using HindIII and XhoI. The resulting constructs were then transfected into Psi 2 cells (46), and cells resistant to G418 (500 µg/ml, Life Technologies, Inc.) were selected, and the total population of cells was propagated in G418 (200 µg/ml). Cellular supernatant from these cells was used to infect PC12nnr5 cells (described below).

Cell Culture and NGF Treatment

PC12 cells and PC12nnr5-derived mutants were grown on collagen-coated tissue culture plates in RPMI 1640 medium (Life Technologies, Inc.) supplemented with 10% heat-inactivated donor horse and 5% fetal bovine serum (both from JRH Biosciences), as described previously (7). Retroviral infections were carried out by adding 0.2-1 ml of virus-containing supernatant, recovered from packaging cell lines, to 50% confluent PC12nnr5 cell cultures (47). Transfections (used in generating cell lines bearing combinations of Y490F, Y751F, and Y785F superposed on triple activation loop mutant background) were carried out by electroporation as described previously (47). Infected/transfected cells were cultured for 1 week and then subjected to selection with G418 (Sigma) for 2 weeks. Surviving colonies were isolated and clonally expanded for characterization. Representative clones were chosen for biochemical assessment on the basis of level of receptor expression and similarity of cellular morphology with that of parental cells.

Neuritogenesis was assessed in cultures grown in RPMI 1640 medium supplemented with 1% heat-inactivated horse serum, as described previously (7, 17). NGF-treated (100 ng/ml) and NGF-untreated cultures were scored for times up to 1 week by determining the presence or absence of neurites on cells chosen at random (n >= 300). Reported values represent the mean values of triplicate experiments conducted with each clonal line. Recombinant hNGF was a generous gift from Genetech Inc.

Immunoprecipitation and Protein Biochemistry

NGF treatment of cultures for biochemical assessments was routinely conducted 1 day following exchange of the culture medium and was accomplished by addition of an aliquot of concentrated stock to a final concentration of 100 ng/ml. After indicated treatment times, cells were washed three times with ice-cold phosphate-buffered saline, were lysed (10% glycerol, 100 mM NaF, 10 mM EGTA, 1 mM Na3VO4, 1% Triton X-100, 50 mM Tris, pH 7.5, 150 mM NaCl, 10 µg/ml aprotinin, 5 µM ZnCl2, 2 mM phenylmethylsulfonyl fluoride, and 1 µg/ml leupeptin), and the lysates were clarified by ultracentrifugation after a 15-min incubation on ice, all as described previously (48). Samples normalized for total protein content were subjected to immunoprecipitation with the indicated antibodies as described previously (15, 48, 49). Protein A-Sepharose beads were from Pharmacia Biotech Inc., and antisera against Shc and PLCgamma -1 were from UBI. Anti-pan Trk (203) and anti-phosphotyrosine (4G10) were used as described previously (15, 48, 49). Immunoprecipitated samples were washed three times in TNTG (20 mM Tris, pH 7.5, 10% glycerol, 0.1% Triton X-100, and 150 mM NaCl) and subjected to SDS-polyacrylamide gel electrophoresis followed by electrophoretic transfer to nitrocellulose (48). Western blotting was conducted with the indicated antibodies using the protocol of Amersham Life Sciences, Inc., followed by visualization by enhanced chemiluminescence (Amersham Corp.). For quantification, data were scanned and analyzed using NIH Scion Image v1.55 software. Blots were reprobed with antibody after stripping in 2% SDS, 100 mM 2-mercaptoethanol, and 62.5 mM Tris, pH 6.8, and rocking at room temperature for >= 16 h.

ERK tyrosine phosphorylation was assessed by subjecting clarified lysates (150 µg of protein) to SDS-polyacrylamide gel electrophoresis and Western immunoblotting with anti-phosphotyrosine. Anti-ERK C-16 antibody was from Santa Cruz Biotechnology. PI3'K activity and SNT tyrosine phosphorylation were assessed as described previously (49-51). Measurements of radiolabeled products in the PI3'K assay were made using a Molecular Dynamics PhosphorImager.

Northern Blotting

Cells treated with NGF for 0, 30, 60, and 120 min were washed three times with ice-cold phosphate-buffered saline, and total RNA was extracted using Tri-Reagent (MRC). Purified RNA was quantified, and 20-µg samples were subjected to Northern blotting as described previously (14, 49, 52). Blots were UV cross-linked and hybridized with probes to c-fos, c-jun, tis 1, tis 8, and tis 11 as described previously (49, 53).


RESULTS

Generation of Cell Lines Stably Expressing TRKs Mutated at Activation Loop Autophosphorylation Sites

To study the biological importance of the tyrosine autophosphorylation sites in the activation loop of TRK, constructs of the human receptor were mutated from tyrosine to phenylalanine at residues 670, 674, and 675, both singly and in all combinations. These and wild type (WT) TRK were cloned into the pLNCX retrovirus vector (54), and the resultant recombinant retroviruses (pLNC-TRKA and mutants) were used to infect the Trk-deficient PC12-derived cell line, PC12nnr5 (16, 52). After selection, approximately two dozen independent clonal lines were isolated and expanded for each receptor construct.

Correlation between Mutant Receptor Expression Levels and NGF-promoted Neuritogenesis

Cell lines representative for a spectrum of WT and mutant TRK levels were chosen for each of the constructs on the basis of analyses carried out by receptor immunoprecipitation followed by quantitative immunoblotting with Trk antiserum (Table I). Expression in each line was compared with that of the PC12nnr5-T14 cell line that over-expresses wild type TRK at levels approximately 3-5-fold higher than PC12 cells (49, 52). Expression of the mutant and wild type TRKs ranged from equal to that of PC12nnr5-T14 cells to 20-50-fold higher. These cell lines were then assessed for NGF-induced neuritogenesis. In general, neurite outgrowth in the cell lines bearing mutant TRKs reached maximal levels by 3-4 days of NGF exposure (data not shown), which is comparable with previous observations for PC12nnr5-T14 cells and other TRK over-expressing PC12-derived cell lines (15, 52, 55).

Table I.

Expression levels of TRK in PC12nnr5 transfectant cell lines


Clone Fold-T14 expressiona Clone Fold-T14 expressiona Clone Fold-T14 expressiona

PC12nnr5-T14 1 Y674F YY670/675FF
Wild type
  3 17  ± 5   12 15  ± 5   3 16  ± 4
  4 13  ± 2   15 11  ± 3   5 23  ± 8
  6 12  ± 1   16 19, 11   9 12, 4
  13 11, 11   19 15, 15   11 10  ± 3
  16 10, 14 Y675F   12 37, 21
  17 1, 2   3 30  ± 11   13 6, 10
  18 9  ± 2   7 10, 9   14 4, 5
  21 18  ± 7   8 1, 1   20 10, 7
Y670F   9 2, 2   21 4, 6
  2 8  ± 2   11 2, 2 YY674/675FF
  4 22, 15   13 6, 9   1 4, 10
  5 12, 9   14 9  ± 4   3 2, 2
  6 6, 5   15 5, 5   4 51, 23
  7 5  ± 2   16 5  ± 3   5 3, 8
  11 3, 1   18 28, 46   12 13  ± 2
  13 14  ± 6   21 4  ± 1   13 38, 28
  16 2, 1 YY670/674FF   14 4, 6
  18 2, 4   2 34, 31   21 8  ± 2
Y674F   6 39  ± 6 YY670/674/675FFF
  4 23, 18   10 55, 42   1 39
  5 8, 4   12 26  ± 6   6 9, 11
  8 1, 4   13 11, 11   8 39
  11 2, 2   17 5  ± 0.5   11 7
  18 6, 3   15 42
  20 16  ± 6   17 8, 8

a TRK expression was quantified by subjecting detergent-solubilized total cell lysates normalized for protein content to immunoprecipitation with anti-Trk (203). The PC12nnr5-T14 cell line was used as a standard of reference in these determinations and was included in parallel in all experiments. Immunoprecipitated samples were then aliquoted and Western immunoblotted with anti-Trk (203), and signals were quantified by densitometry as described under "Materials and Methods." Quantifications of TRK expression are reported as raw values or as the average of one to four independent experiments (±S.E., where applicable) and are given as relative to the level of TRK in PC12nnr5-T14 cells.

Comparison of the maximal neuritogenic responses in cell lines expressing comparable levels of each of the different TRK mutants revealed dramatic differences. For example, following a vertical path in Fig. 1D at the level of TRK expression corresponding to 10-fold that in PC12nnr5-T14 cells shows that none of the multiply-mutated TRKs confer NGF-dependent neuritogenesis, whereas the Y675F receptors confer responsiveness in 10-15% of cells, and Y670F and Y674F receptors confer responsiveness in 50% of cells. Moreover, when neuritogenic extent was correlated over a range of receptor expression levels, dose-response relationships became apparent (Fig. 1). These plots revealed several important points. First, receptor expression levels significantly affect biological responsiveness (especially evident for the WT, Y670F, and Y674F TRKs) and therefore must be considered when interpreting assessed phenotypes. Second, each of the activation loop mutations impairs receptor function to at least some degree. This is demonstrated by the shifts in dose-responsiveness to NGF for cells expressing mutant TRKs as compared with cells expressing wild type TRK (Fig. 1, D and E). Even those mutant TRKs conferring the greatest neurite outgrowth responses (i.e. Y670F and Y674F) had to be expressed at levels 3-5-fold higher than present in PC12nnr5-T14 cells to achieve significant neuritogenesis. Third, there exists a hierarchy for restoration of neuritogenesis as a function of receptor over-expression in the various TRKs: WT > Y670F >=  Y674F >>  Y675F >=  YY670/674FF = YY670/675FF >> YY674/675FF > YYY670/674/675FFF. Overall, the degree of rescue achievable shows that the mutants fall into three general groupings (Fig. 1D). The WT, and Y670F and Y674F TRKs are each capable of mediating near-complete levels of neuritogenesis, although the two mutant TRKs require higher expression to achieve this. The second group of receptors (Y675F, YY670/674FF, and YY670/675FF), even when greatly over-expressed, mediate only partial restoration of neurite outgrowth. An important point is that the degree of impairment achieved by the Y675F mutation is much greater than that caused by the other two single mutations, Y670F and Y674F. The third group includes YY674/675FF and YYY670/674/675FFF. These lack the ability to mediate neuritogenesis, irrespective of expression level. Collectively, these observations indicate that TRKs mutated at different activation loop tyrosines have differing capacities to functionally rescue NGF-dependent responses. This is due to both the type of mutation assessed and the level to which it is expressed.


Fig. 1. Expression-dependent mediation of NGF-promoted neuritogenesis by PC12nnr5 lines expressing wild type and mutated TRKs. NGF-promoted neuritogenesis was assessed as described under "Materials and Methods" for PC12nnr5 cells expressing the indicated relative levels of wild type and mutated TRK receptors. The values reported are averages (± S.E.) derived from three independent experiments and were determined at a 1-week time point. The identity of the various constructs are indicated in A-D and the particular lines are listed in Table I. E, is included to aid in interpretation of D at TRK expression levels equal to or below 10-fold that found in PC12nnr5-T14 cells. A, square , wild type; open circle , Y670F; triangle , Y675F. B, diamond , Y674F; box-plus , YY670/674FF; down-triangle, YYY670/674/675FFF. C, black-lozenge , YY670/675FF; oplus , YY674/675FF. D, square , wild type; open circle , Y670F; diamond , Y674F; triangle , Y675F; box-plus , YY670/674FF; black-lozenge , YY670/675FF; oplus , YY674/675FF; down-triangle, YYY670/674/675FFF. E, square , wild type; open circle , Y670F; diamond , Y674F; triangle , Y675F; box-plus , YY670/674FF; black-diamond , YY670/675FF; oplus , YY674/675FF; down-triangle, YYY670/674/675FFF.
[View Larger Version of this Image (27K GIF file)]


NGF-inducible Tyrosine Autophosphorylation of Activation Loop Mutant TRK Receptors and Assessment of NGF-induced Signaling through Shc, the ERKs, SNT, and Immediate Early Genes

Our neuritogenesis studies revealed that for partially compromised receptors, the expression levels of TRK receptors can significantly influence the degree to which they mediate biological responses. To control for this, we therefore assessed additional parameters in cell lines expressing comparable levels of different mutant receptors, as well as in cell lines expressing different levels of each individual TRK mutant. Two cell lines were selected for each of the constructs, one expressing receptors at approximately 5-fold, and the second at approximately 10-25-fold higher than expressed by PC12nnr5-T14 cells. Cell lines with TRK expressed at lower levels were not assessed for biochemical responses, due to their lack of neuritogenic responses (Fig. 1).

To assess NGF-promoted Trk tyrosine autophosphorylation, cultures were treated with or without 100 ng/ml NGF for 5 min. Lysates were normalized for protein content, subjected to immunoprecipitation with Trk antibody, and immunoprecipitates subjected to Western blotting and sequentially probed with anti-phosphotyrosine and anti-Trk (Fig. 2). All of the TRK mutants showed NGF-inducible tyrosine phosphorylation, including those in which all three of the activation loop tyrosines were replaced with phenylalanine (Fig. 2A). However, while autophosphorylation was evident with all of the mutants, it was clearly reduced as compared with wild type Trk (as judged by qualitative ratios of anti-phosphotyrosine to anti-Trk signals, even after taking into consideration the numbers of mutated tyrosines). Moreover, the deficits in NGF-induced autophosphorylation of the TRK mutants were not rescueable by receptor over-expression (Fig. 2B) nor were they attributable to altered kinetics of activation when assessed over a time course of several hours (data not shown). Furthermore, the levels of receptor autophosphorylation did not correlate well with the capacity of the TRK mutants to mediate neurite outgrowth. For instance, although the single mutants (Y670F, Y674F, and Y675F) showed comparable levels of NGF-stimulated TRK tyrosine autophosphorylation, as noted above, TRK Y675F was much less effective in mediating neuritogenesis.


Fig. 2. NGF-induced autophosphorylation of wild type and various mutant TRKs expressed in PC12nnr5 cells. Detergent-solubilized protein cell lysates (containing 2 mg of protein) from NGF-treated and control cells were subjected to immunoprecipitation with anti-pan-Trk (203) as described under "Materials and Methods." The immunoprecipitates were subjected to Western immunoblotting and were serially probed with anti-phosphotyrosine (4G10) and anti-Trk (203). Expression-matched cell lines (5-fold (A) or 10-25-fold (B) PC12nnr5-T14 cell expression) bearing the indicated mutant receptors were compared with each other and to PC12 and PC12nnr5-T14 (T14) cells.
[View Larger Version of this Image (41K GIF file)]


Trk activation by NGF in PC12 cells and PC12nnr5 cells expressing wild type TRK leads to rapid tyrosine phosphorylation of the Shc (15, 56, 57) and ERK (58, 59) proteins, both elements of the Ras signaling pathway. Studies using TRK mutants have revealed that Shc interacts with TRK via phosphotyrosine 490 and that this interaction is required for NGF-dependent Shc tyrosine phosphorylation (15, 60). ERK activation is downstream of Shc and Ras activation and has been implicated as a necessary component of the mechanism by which NGF promotes neurite outgrowth in PC12 cells (15, 49, 58, 59, 61-67). Immunoprecipitation and Western immunoblotting were used to assess NGF-promoted Shc tyrosine phosphorylation at a 5-min time point in cell lines expressing wild type and activation loop mutants of TRK. Observations generally correlated with those found for TRK autophosphorylation and neuritogenesis in that single mutants were significantly more functional than combination mutants and that even single mutants required over-expression (as compared with WT receptors) to yield significant Shc phosphorylation (Fig. 3A). In addition, as anticipated, lines with 10-25-fold over-expression showed greater activation than those with 5-fold over-expression (data not shown). The one case in which Shc phosphorylation and neuritogenesis potential did not correlate well was for the Y675F mutant which was about equal in activity to Y670F and Y674F but significantly less effective in mediating neurite outgrowth.


Fig. 3. NGF-induced tyrosine phosphorylation of Shc and the ERK kinases is decreased but not abrogated by mutation of TRK activation loop tyrosines. A, PC12 cells, PC12nnr5-T14 (T14) cells, and expression-matched activation loop mutant cell lines expressing TRK at levels approximately 5-fold that of PC12nnr5-T14 cells were NGF-treated, or not, for 5 min, and detergent-solubilized lysates were prepared as described under "Materials and Methods." Samples normalized for protein were subjected to anti-Shc immunoprecipitation followed by serial immunoblotting with anti-phosphotyrosine (4G10) and anti-Shc. B, lysates prepared identically to those in A were subjected to Western immunoblotting as described under "Materials and Methods," and blots were serially probed with 4G10 and anti-ERK 1 (C-16) antibodies.
[View Larger Version of this Image (43K GIF file)]


Studies to assess NGF-promoted tyrosine phosphorylation of the ERK kinases in lines with WT and mutant TRKs were carried out at the 5-min time point by subjecting cell lysates to Western immunoblotting. NGF-stimulated ERK tyrosine phosphorylation signal intensities closely paralleled the neuritogenic behavior of the lines (Figs. 1 and 3B). A time course study (up to 10 h) with lines expressing the singly mutated receptors revealed that the Y675F construct showed both lower signal intensity and significantly shorter signal duration when compared with WT, Y670F, and Y674F TRKs (data not shown). This further supports the correlation between neuritogenic activities of the receptors and capacity to stimulate ERK tyrosine phosphorylation.

PC12 cells, or PC12nnr5 cells expressing WT TRK, undergo NGF-dependent tyrosine phosphorylation of the p13 suc1 agarose associating tyrosine-phosphorylated nuclear localized protein (SNT), which appears to be a differentiation-specific signaling molecule in these cells (49, 51). A recent study (49) further supports a role for SNT in PC12 cell neuronal differentiation by establishing that deletion of a conserved juxtamembrane motif (KFG) in TRK selectively renders it incapable of activating the pathway leading to phosphorylation of SNT and that PC12nnr5 cells expressing these mutant receptors are unable to promote neuritogenesis in response to NGF. Although SNT phosphorylation requires the KFG motif (49), it is not dependent on phosphorylation of Tyr-490 or Tyr-785. To determine if the activation loop mutations in TRK affect the NGF-induced tyrosine phosphorylation of SNT, cell lines expressing wild type and activation loop mutant receptors were assessed for this parameter both before and after treatment with NGF for 5 min. As illustrated in Fig. 4, all activation loop mutations impair SNT tyrosine phosphorylation in response to NGF, and very high over-expression of mutant receptors (e.g. YY670/674FF) can rescue NGF-promoted SNT phosphorylation to levels near those observed in wild type PC12 cells. Comparison of these data with those in Fig. 1 reveals that SNT phosphorylation was detectable in all lines capable of NGF-stimulated neurite outgrowth and was undetectable in lines incapable of neuritogenesis. This correlation is consistent with a required role for SNT phosphorylation in promotion of neurite outgrowth. In addition, these findings indicate that although SNT tyrosine phosphorylation does not require autophosphorylation of TRK Tyr-490 and Tyr-785, it is dependent on autophosphorylation of the activation loop tyrosines.


Fig. 4. NGF-induced tyrosine phosphorylation of SNT is impaired but not abolished by mutation of TRK activation loop tyrosines. Clarified lysates were prepared from control and NGF-treated cells as described under "Materials and Methods." SNT was recovered from samples containing equal levels of total proteins using p13suc1-Sepharose and was subjected to Western immunoblotting with anti-phosphotyrosine (4G10). Samples are from PC12, PC12nnr5-T14 (T14), WT.13, and expression-matched activation loop mutant cell lines expressing TRK at levels 10-25-fold that of PC12nnr5-T14.
[View Larger Version of this Image (64K GIF file)]


Stimulation of Trk and downstream signaling pathways by NGF promotes the induction of a number of immediate early genes (68, 69). To determine the effects of the activation loop Trk mutations and consequent alterations in intracellular signaling on induction of these genes, cell lines expressing wild type or mutant TRKs were treated with NGF for 0, 30, 60, and 120 min and assessed by Northern blotting for levels of c-fos, c-jun, tis 1 (NGFI-B), tis 8 (NGFI-A), and tis 11 mRNA. These experiments revealed that the extent of immediate early gene induction generally paralleled neuritogenic potential and ERK activation. Thus, at over-expression levels 5-10-fold that of PC12nnr5-T14 cells, the single mutants all exhibited NGF-promoted levels of gene inductions comparable with those of PC12nnr5-T14 cells; the YY670/674FF and YY670/675FF bearing cell lines showed induction only when the receptors were over-expressed by 10-20-fold relative to the level of TRK expressed in PC12nnr5-T14 cells; the YY674/675FF lines do not respond unless expressed to levels over 30-fold higher than PC12nnr5-T14 cells; and the YYY670/674/675FFF lines that we have assessed had no detectable responses. The one anomaly was the Y675F lines that exhibited immediate early gene responses similar to those of lines with the other single activation loop mutations but which showed relatively poor neuritogenesis.

NGF-mediated Tyrosine Phosphorylation of PLCgamma -1 Is Abrogated in Cells Expressing TRK Activation Loop Mutant Receptors

Autophosphorylation of TRK at Tyr-785 results in binding, tyrosine phosphorylation, and activation of PLCgamma -1 (14, 15, 18, 70). To assess the effect of activation loop mutations on NGF-promoted tyrosine phosphorylation of PLCgamma -1, lysates were prepared from cells treated with NGF for 5 min and were subjected to immunoprecipitation with anti-PLCgamma -1 antibody. Immunoprecipitated PLCgamma -1 was sequentially probed in Western blot experiments with anti-phosphotyrosine and anti-PLCgamma -1 antibodies. As shown in Fig. 5, NGF-induced PLCgamma -1 tyrosine phosphorylation was undetectable, or greatly diminished, in all activation loop mutant cell lines tested, including those with high receptor over-expression and those that mediate robust neurite outgrowth. In contrast, NGF treatment of cells expressing wild type Trk (PC12, PC12nnr5-T14 and PC12nnr5-WT.13) resulted in PLCgamma -1 tyrosine phosphorylation. Therefore, any mutation of the activation loop tyrosines renders TRKA highly impaired for tyrosine phosphorylation of PLCgamma -1.


Fig. 5. NGF-induced PLCgamma -1 activation is abrogated by mutation of activation loop tyrosines. NGF-treated and control cells were lysed and total proteins were prepared as described under "Materials and Methods." Samples normalized for protein were subjected to immunoprecipitation with anti-PLCgamma -1, and the immunoprecipitates were analyzed by Western immunoblotting using anti-phosphotyrosine (4G10) and anti-PLCgamma -1 as probes. Samples are from PC12, PC12nnr5-T14 (T14), and expression-matched activation loop mutant cell lines expressing TRK at levels 5-fold (A) or 10-25-fold (B) that of PC12nnr5-T14 cells.
[View Larger Version of this Image (38K GIF file)]


To determine if this impairment was attributable to abrogated interaction between PLCgamma -1 and TRK activation loop mutants, we assessed the ability of these proteins to co-immunoprecipitate. Samples prepared as above were subjected to immunoprecipitation with anti-PLCgamma -1 antibody, Western blotted, and sequentially probed with antisera/antibodies against Trk, phosphotyrosine (4G10), and PLCgamma -1. Lysates from NGF-treated cells bearing WT receptors yielded co-immunoprecipitation of PLCgamma -1 and an anti-Trk immunoreactive band migrating at 140 kDa (data not shown). This Trk-immunoreactive band co-migrates with a prominent anti-phosphotyrosine-immunoreactive band (Fig. 5), consistent with its identification as tyrosine-phosphorylated TRKA. In contrast, no anti-Trk signals were detected in PLCgamma -1 immunoprecipitates from NGF-treated cells expressing even single Tyr to Phe activation loop mutations (data not shown). Re-probing of the blots with anti-phosphotyrosine confirmed that little or no tyrosine phosphorylated TRK co-immunoprecipitates with PLCgamma -1 in any of the activation loop mutants, even at very high levels of over-expression (Fig. 5). Therefore, the inability of TRK activation loop mutant receptors to phosphorylate PLCgamma -1 appears to be due to impaired interaction between the receptors and PLCgamma -1.

NGF-mediated Induction of PI3'K Activity Is Undetectable in Cells Expressing TRK Activation Loop Mutant Receptors

Phosphatidylinositol 3'-kinase (PI3'K) activity is an additional signaling enzyme that is activated by NGF in PC12 cells (50) and implicated as a mediator of both neuritogenesis and survival (71, 72). The mechanism of PI3'K activation is not clear, but recent findings appear to implicate tyrosine 490 as a major determinant of NGF-mediated PI3'K activation (70).2 PI3'K activity was assessed in vitro in cell lines expressing wild type and activation loop mutant TRKs treated for 5 min with NGF. As illustrated in Fig. 6, PI3'K activity was induced by NGF 2-3-fold in PC12 cells, 6-10-fold in PC12nnr5-T14 cells, and 3-6-fold in the PC12nnr5-WT.13 cell line. In contrast, no PI3'K activity was reproducibly induced by NGF treatment in any of the cell lines expressing the mutant TRKs, including those with very high levels of receptor over-expression. Thus, as in the case of PLCgamma -1, all of the activation loop mutations, including those affecting single tyrosines, abolished detectable NGF-induced PI3'K activation. An additional effect revealed by our analyses was that, on a per mg of cell protein basis, the basal levels of PI3'K activity in those lines with highest over-expression of mutant receptors were consistently elevated 3-10-fold when compared with basal levels in PC12nnr5-T14 cells (data not shown). The latter observation raises the possibility that very high over-expression of mutated TRKs may lead to at least some degree of constitutive PI3'K activation.


Fig. 6. NGF-induced PI3'K activation is undetectable in cell lines with mutant TRK receptors. Total proteins were prepared from control and NGF-stimulated PC12, PC12nnr5-T14 (T14), WT.13, and activation loop mutant cell lines at two receptor expression levels, and anti-phosphotyrosine-immunoprecipitable PI3'K kinase activity was assessed as described under "Materials and Methods." Results are presented as the ratios of activity induced by NGF treatment over basal activity. Error bars represent the range of duplicate experiments (n = 2). Open box, >= 5 × fold; box with lines, >= 10-25 × fold.
[View Larger Version of this Image (23K GIF file)]


Mutation of Any TRK Activation Loop Tyrosine Compromises Autophosphorylation of Tyr-785

To extend our experiments on autophosphorylation and activation of signaling molecules, we generated and examined cell lines expressing TRK mutants in which the activation loop triple mutant was combined with tyrosine to phenylalanine mutations of residues Tyr-490, Tyr-751, and Tyr-785, singly and in combination. As noted above, the latter are the TRK tyrosine autophosphorylation sites not contained in the activation loop and are responsible for binding and/or activating Shc, PI3'K, and PLCgamma -1. Initial characterization of these cell lines revealed that, like the triple mutants, they failed to mediate both NGF-promoted ERK activation and neuritogenesis (data not shown). As shown in Fig. 7, analysis of the various lines indicated that basal and NGF-promoted tyrosine autophosphorylation of the mutant receptors were maintained by those mutants that retained Tyr-490 and were absent in those that had this site mutated, despite the simultaneous presence of Tyr-785 and Tyr-751. Previous work has demonstrated that the Y490F mutation alone in otherwise unmodified hTRK receptors does not impair TRK tyrosine autophosphorylation, either overall or at Tyr-785 (15, 73) and thus is not a first step in the TRK autophosphorylation mechanism. The present findings indicate that the tyrosine autophosphorylation observed in the triple activation loop TRK mutants occurs solely at the Tyr-490 position. This observation, taken together with the receptor autophosphorylation and PLCgamma -1 signaling data, is consistent with the prediction that mutation of any of the activation loop tyrosines disrupts TRK autophosphorylation at Tyr-785.


Fig. 7. NGF-inducible autophosphorylation of activation loop mutant TRK receptors occurs at tyrosine 490. PC12nnr5-derived cell lines expressing mutated receptors were assessed for NGF-promoted TRK tyrosine autophosphorylation. Receptor mutations present in various lines are indicated in the figure. Cells were treated with NGF, or not, and cell lysates were prepared as described under "Materials and Methods." Samples containing equal amounts of total cell protein were subjected to immunoprecipitation with anti-pan-Trk (203) and sequentially immunoblotted with anti-phosphotyrosine (4G10) and anti-Trk (203).
[View Larger Version of this Image (62K GIF file)]



DISCUSSION

The purpose of the present study was to characterize the roles of the putative autophosphorylation activation loop tyrosines in the TRK receptor. This was achieved by mutating these tyrosines singly, and in all combinations, and then examining the signaling properties of each mutant receptor when stably expressed at various levels in PC12nnr5 cells that lack endogenous Trk. The use of PC12-derived cells permitted us to carry out our investigation in a background that displays neuronal phenotypic properties that include neurite outgrowth.

Level of Mutant TRK Expression Affects Responsiveness to NGF

An important feature here is that TRK-transfected cell lines were studied over a range of receptor expression. Examining NGF-induced responses in this manner provided means to take TRK protein expression into account and revealed that each of the tyrosines in the activation loop plays an important role in regulating NGF responsiveness. In many cases, the presence and degree of functional impairment induced by particular receptor loop mutations could be masked by over-expression. Thus, lines expressing several of the activation loop receptor mutants exhibited wild-type responses, and functional impairment of the mutant receptors was detected only by comparing dose-response curves for cell lines expressing mutant and non-mutant receptors. Such findings raise a general cautionary note for studies in which mutant receptors are functionally evaluated by exogenous introduction into cell lines; in these cases, expression level is likely to be an important determinant of apparent preservation of function.

Activation Loop Mutations Affect Total Receptor Autophosphorylation

Our findings demonstrate that mutation of any one of the three activation loop tyrosines in TRK results in substantial and essentially equal reduction of NGF-mediated receptor tyrosine autophosphorylation. Likewise, further decreases in TRK tyrosine autophosphorylation occur with the combined mutation of any two tyrosines, and an additional reduction occurs in response to mutation of the third tyrosine. Autophosphorylation impairment appears to be independent of both receptor expression level and autophosphorylation kinetics. Additionally, the decrements in autophosphorylation do not appear to be attributable simply to reduction of the number of available substrate tyrosine residues, because the relative loss of TRK tyrosine phosphorylation is not proportional to the number of sites mutated, especially with regard to single tyrosine mutants. One potential contribution to the dramatic loss of tyrosine autophosphorylation during the transition from WT to single activation loop tyrosine mutant is provided by our finding that tyrosine 785 is not autophosphorylated in activation loop mutant receptors. Observations with other RTKs, and principally the insulin receptor, indicate that the extent of autophosphorylation correlates with activation of kinase activity (1, 34, 74-79). Therefore, an additional major factor in the reduction of autophosphorylation observed in the mutated TRK receptors appears to be impairment of receptor kinase activity necessary for efficient autophosphorylation.

Mutations homologous to those studied here have been carried out with several other RTKs, and they appear to show some variation from one case to the next with respect to their effect on both ligand-stimulated autophosphorylation and biological responses (34, 44, 80, 81). However, all combinations of these mutations have not been assessed in each of these systems. Findings for autophosphorylation of the insulin receptor closely resemble those for TRK in that single mutations substantially, and about equally, decrease ligand-stimulated receptor autophosphorylation, and mutation of additional tyrosines results in more severe impairment (38, 39). With regard to biological responses, however, there are differences. For example, mutation of the insulin receptor tyrosine equivalent to TRK Tyr-670 abolished thymidine incorporation but not metabolic responses (38, 41), whereas mutation of the tyrosine equivalent to TRK Tyr-674 and Tyr-674/675 compromised 2-deoxyglucose uptake and activation of glycogen synthase but not thymidine incorporation (29, 38). This somewhat contrasts with our findings for TRK-mediated signaling, in that we observed no such dissection of function, as both of our downstream correlates of receptor function (neurite outgrowth and immediate early gene induction) were adversely affected by mutation of any of the activation loop tyrosines.

For the c-Met/hepatocyte growth factor (HGF) receptor, the consequences for activation loop mutations yielded a hierarchical loss of RTK autophosphorylation which, when expressed in sites equivalent to those in TRKA, were WT = Y670F > Y674F >>  Y675F and in which the mutant equivalent to YY674/675FF lost all activity (34). It was further reported that mutation of sites equivalent to either Tyr-674 or Tyr-675 abolished a cell migration response to HGF (34) or to EGF in a chimeric-receptor paradigm (33). In the case of the IGF-I receptor, mutations equivalent to Y670F and Y674F appeared to cause a moderate decrease in receptor autophosphorylation and to have no effect on mitogenic responsiveness to IGF, whereas the mutation equivalent to Y675F abolished both receptor autophosphorylation and mitogenicity in response to IGF (42, 44). In contrast, assessment of IGF-dependent growth on soft agar showed functional impairment for all of the singly mutated receptors (44). Collectively, these findings further illustrate that there are both similarities and distinctions between the roles of individual homologous activation loop tyrosines in different RTKs.

TrkB, which is highly homologous to TrkA in kinase domain sequence and presumably in overall intracellular structure, has been mutated at the equivalent of TRKA positions Tyr-670 and Tyr-674/675 and expressed in cell lines (80, 81). The single mutation was reported to be without effect on either autophosphorylation or activation of a transcription reporter gene, whereas cells bearing the double mutants were greatly impaired in both assessed phenotypes. Although the effects of the TrkB Y670F mutation appear to be in contrast with our findings, a more likely explanation is that, as with TRKA, a high degree of function may have been rescued by over-expression.

Effect of Activation Loop Mutations on Substrate Tyrosine Phosphorylation

Effects of mutations on receptor signaling may be due to global actions on catalytic activity as well as to differential effects on phosphorylation of specific tyrosine residues and/or of specific substrates. A surprising and novel observation here was that mutation of any one or more of the activation loop tyrosines in TRK blocks the NGF-dependent induction of PI3'K activity and tyrosine phosphorylation of PLCgamma -1. In contrast, NGF-promoted Shc phosphorylation, although compromised, was not significantly reduced in the cases of single site mutations and several of the double site mutations. The most likely explanation for the effect on PLCgamma -1 tyrosine phosphorylation is that mutation of any of the activation loop tyrosines selectively compromises NGF-promoted receptor autophosphorylation of Tyr-785 in the C terminus of the receptor. This mechanism would account for the loss of NGF-induced co-immunoprecipitation of PLCgamma -1 and mutated TRK, and the loss of PLCgamma -1 tyrosine phosphorylation in response to NGF treatment in all of the TRK mutants assessed. We directly demonstrated this mechanism in the triply-mutated TRK background, where NGF-stimulated TRK autophosphorylation was retained only in receptors with an intact Tyr-490 (Fig. 7), therefore indicating that Tyr-785 was not being phosphorylated. This potential mechanism recapitulates previous studies in which TRK tyrosine 785 was mutated to phenylalanine, which eliminated phosphorylation at this position, and consequently abolished binding and activation of PLCgamma -1 (14, 18). Taken together, our observations indicate that mutation of any of the activation loop tyrosines selectively abrogates tyrosine phosphorylation of Tyr-785 and, consequently, binding and activation of PLCgamma -1.

Although loss of PI3'K activation would have a similar mechanistic explanation if association of this enzyme with TRK was mediated via phospho-Tyr-751 (60, 82), recent findings suggest that TRK-evoked PI3'K activation is mediated by Tyr-490 (70).2 In this case, the differential loss of PI3'K activity, vis à vis the partially preserved Shc tyrosine phosphorylation, could be explained by a difference in the threshold of TRK kinase activity necessary for generation of a functional and biochemically detectable signal. For example, if PI3'K activity is dependent upon Shc-mediated activation of Ras (83, 84), then the reduction of Shc tyrosine phosphorylation observed for the single mutants could completely impair PI3'K activation by falling below a given critical level, while simultaneously maintaining partial activation of other signaling molecules downstream of Ras (e.g. ERKs). In agreement with this idea of a threshold effect, wild type PC12 cells show relatively poor NGF-mediated PI3'K activation, and TRK over-expression results in substantially enhanced responses. An alternative suggestion for the lack of PI3'K activation is provided by recent findings of a feedback mechanism in which phosphatidylinositol kinase products block the association of phosphatidylinositol kinases with tyrosine-phosphorylated proteins/RTKs (85). We found that basal PI3'K activity was elevated in cell lines highly over-expressing activation loop mutant TRKs, which is consistent with the production of phosphatidylinositol kinase products in the absence of NGF. It is possible that these products block association of the p85 subunit of PI3'K with TRK, even in the presence of NGF, thereby blocking NGF-dependent increases in PI3'K activity.

The differential consequences that activation loop tyrosine mutations have on autophosphorylation of specific sites in the TRK receptor may also pertain to other RTKs. Tavare and Dickens (91) presented evidence that mutation of the site homologous to TRK Tyr-674 in the insulin receptor leads to abolition of autophosphorylation at two C-terminal tyrosine residues. Although effects on autophosphorylation at other sites were not reported in this case, it is of interest that autophosphorylation of insulin receptor substrate 1, which binds to insulin receptors toward the N-terminal side of the kinase domain, is only partially impaired in response to mutation of the tyrosine equivalent to TRK Tyr-670 (38, 39). Differential, site-specific effects on autophosphorylation may also account for the observation that mutation of the insulin receptor site equivalent to TRK Tyr-670 abolishes insulin-stimulated thymidine incorporation but not activation of glycogen synthetase (41).

Despite loss of signaling through PI3'K and PLCgamma -1, TRK receptors with single activation loop mutations were still able to mediate differentiative responses to NGF. This is consistent with past observations that PLCgamma -1 tyrosine phosphorylation is not required for neurite outgrowth (14, 73). Our present results extend these observations, for both PLCgamma -1 and PI3'K, to NGF-inducible downstream signaling responses such as induction of immediate early genes. It has been reported that wortmannin, an inhibitor of PI3'K, blocks NGF-stimulated neurite outgrowth (71). If such effects are entirely due to PI3'K inhibition, then our findings suggest that the observed elevated basal PI3'K activity reported for over-expressing activation loop mutant cell lines, rather than NGF-stimulated PI3'K activity, is sufficient for neuritic outgrowth. Alternatively, the wortmannin used in previous studies may have inhibited the activity of other proteins, in addition to PI3'K, required for this response.

The presence of biological responses to NGF in cells bearing receptors mutated at activation loop tyrosines must be interpreted with respect to those pathways that although impaired are partially functional. At present, this includes the Shc/Ras pathway and the pathway defined by the TRK Delta KFG mutation that involves SNT. Past findings have indicated that both of these pathways may play roles in neuritogenesis and immediate early gene regulation in PC12 cells (15, 49, 73). This is consistent with findings here in which neurite outgrowth and gene regulation generally correlate with the extent of NGF-stimulated Shc and SNT tyrosine phosphorylation. Nevertheless, there were several apparent exceptions to this observation. One was that for the Y675F mutants, neuritogenic responses and ERK activation were relatively weak even when Shc tyrosine phosphorylation was strong. This suggests that there may be an additional TRK/Tyr-675-regulated element that plays a role in the signaling between Shc and ERKs. A second discrepancy was that the triple activation loop TRKs appeared capable of autophosphorylating Tyr-490 but showed little if any phosphorylation of Shc. One possible interpretation of this is that the kinase activity in these mutants is sufficient to autophosphorylate the receptor and thereby promote binding of Shc but is impaired with respect to phosphorylation of this substrate; such a mechanism appears to occur in the TRK Y751F mutant.3

Function of Receptor Loop Tyrosines in TRK Activation

As a first approximation, activation of TRK by NGF likely parallels the intensively studied process by which insulin receptors are activated. In the latter case, the activation loop appears to block access of ATP and of substrates to the catalytic core of non-activated receptors (37). The crystal structure of the insulin receptor kinase domain has suggested that blockade of substrate access is due, at least in part, to interaction of tyrosine 1162 (corresponding to Tyr-674 in TRK) with a critical aspartate residue in the catalytic core. Ligand binding appears to cause a change in receptor conformation (which, in the case of Trk would include receptor dimerization), which permits trans-autophosphorylation of the activation loop tyrosines (86-88). This phosphorylation, and consequent change in charge, is hypothesized to bring the activation loop into a conformation which no longer inhibits substrate access and which permits the activated receptor to further trans-phosphorylate itself as well as receptor-associated substrates (37, 89, 90). Even for the insulin receptor, the roles in this process of the activation loop tyrosines other than Tyr-1162 are presently unknown.

As appears to be the case for the insulin receptor and at least several other RTKs that possess homologous activation loops, phosphorylation of all three tyrosines is required for optimal activation of TRK. Our dose-response observations concerning neurite outgrowth and receptor occupancy indicate that there is a hierarchical order in which mutation of these sites, singly and in combinations, impairs function. Significantly, we also found evidence that autophosphorylation of TRK Tyr-785 appears to be abolished by mutation of even a single activation loop tyrosine. This suggests that phosphorylation of all three activation loop tyrosines causes, and is required for, a change in conformation that permits interaction between the catalytic core and C-terminal tyrosine residues. One model to account for this would be that after the activation loop tyrosines are phosphorylated, each interacts with specific nearby basic residues to stabilize a conformation that promotes full activation of the receptor kinase, including access to the C-terminal region. In this model, autophosphorylation of the activation loop tyrosines would function both to relieve inhibition of kinase activity as well as to stabilize a new, optimally active conformation.


FOOTNOTES

*   This work was supported by grants from the National Institutes of Health, NINDS, and March of Dimes Birth Defects Foundation (to L. A. G.), Medical Scientist Training Program Grant MSTP 5 T32 GM07367 (to M. E. C.), and by a contract with the National Cancer Institute, DHHS, with ABL (to D. R. K. and R. M. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
par    To whom correspondence should be addressed: Dept. of Pathology and Center of Neurobiology and Behavior, College of Physicians and Surgeons, Columbia University, 630 West 168th St., P & S Bldg., Rm. 15-401, New York, NY 10032. Tel.: 212-305-6369 or 212-305-6370; Fax: 212-305-5498; E-mail: LAG3{at}Columbia.edu.
1   The abbreviations used are: RTK, receptor tyrosine kinase; WT, wild type; NGF, nerve growth factor; Shc, Src homology and collagen; ERK, extracellular signal-regulated kinase; SNT, p13 suc1 agarose associating tyrosine-phosphorylated nuclear localized protein; PI3'K, phosphatidylinositol 3'-kinase; PLCgamma -1, phospholipase Cgamma -1; SH2, Src homology 2; IGF, insulin-like growth factor I; HGF, hepatocyte growth factor.
2   B. Hallenberg, R. M. Stephens, D. R. Kaplan, D. M. Loeb, L. A. Greene, and J. Downward, unpublished data.
3   X. Peng, M. E. Cunningham, R. M. Stephens, D. R. Kaplan, and L. A. Greene, manuscript submitted for publication.

ACKNOWLEDGEMENTS

R. M. S. and D. R. K. thank George VandeWoude and the ABL-BRP for their generous support.


REFERENCES

  1. van der Geer, P., Hunter, T., and Lindberg, R. A. (1994) Annu. Rev. Cell Biol. 10, 251-337 [CrossRef]
  2. Schlessinger, J., and Ullrich, A. (1992) Neuron 9, 383-391 [Medline] [Order article via Infotrieve]
  3. Ip, N. Y., Stitt, T. N., Tapley, P., Klein, R., Glass, D. J., Fandl, J., Greene, L. A., Barbacid, M., and Yancopoulos, G. D. (1993) Neuron 10, 137-149 [Medline] [Order article via Infotrieve]
  4. Glass, D. J., and Yancopoulos, G. D. (1993) Trends Cell Biol. 3, 262-268 [CrossRef]
  5. Kaplan, D. R., Hempstead, B. L., Martin-Zanca, D., Chao, M. V., and Parada, L. F. (1991) Science 252, 554-558 [Medline] [Order article via Infotrieve]
  6. Klein, R., Jing, S., Nanduri, V., O'Rourke, E., and Barbacid, M. (1991) Cell 65, 189-197 [Medline] [Order article via Infotrieve]
  7. Greene, L. A., and Tischler, A. S. (1976) Proc. Natl. Acad. Sci. U. S. A. 73, 2424-2428 [Abstract]
  8. Greene, L. A., and Tischler, A. S. (1982) Adv. Cell. Neurobiol. 3, 373-414
  9. Kaplan, D. R., and Stephens, R. M. (1994) J. Neurobiol. 25, 1404-1417 [Medline] [Order article via Infotrieve]
  10. Greene, L. A. (1984) Trends Neurosci. 7, 91-94
  11. Keegan, K., and Halegoua, S. (1993) Curr. Opin. Neurobiol. 3, 14-19 [Medline] [Order article via Infotrieve]
  12. Jing, S., Tapley, P., and Barbacid, M. (1992) Neuron 9, 1067-1079 [Medline] [Order article via Infotrieve]
  13. Greene, L. A., and Kaplan, D. R. (1995) Curr. Opin. Neurobiol. 5, 579-587 [CrossRef][Medline] [Order article via Infotrieve]
  14. Loeb, D. M., Stephens, R. M., Copeland, T., Kaplan, D. R., and Greene, L. A. (1994) J. Biol. Chem. 269, 8901-8910 [Abstract/Free Full Text]
  15. Stephens, R. M., Loeb, D. M., Copeland, T. D., Pawson, T., Greene, L. A., and Kaplan, D. R. (1994) Neuron 12, 1-20 [Medline] [Order article via Infotrieve]
  16. Green, S. H., Rydel, R. E., Connolly, J. L., and Greene, L. A. (1986) J. Cell Biol. 102, 830-843 [Abstract]
  17. Loeb, D. M., Maragos, J., Martin-Zanca, D., Chao, M. V., Parada, L. F., and Greene, L. A. (1991) Cell 66, 961-966 [Medline] [Order article via Infotrieve]
  18. Obermeier, A., Halfter, H., Wiesmüller, K.-H., Jung, G., Schlessinger, J., and Ullrich, A. (1993) EMBO J. 12, 933-941 [Abstract]
  19. Cantley, L. C., and Songyang, Z. (1994) J. Cell Sci. 18, (suppl.) 121-126
  20. van der Geer, P., Wiley, S., Lai, V. K.-M., Olivier, J. P., Gish, G. D., Stephens, R., Kaplan, D., Shoelson, S., and Pawson, T. (1995) Curr. Biol. 5, 404-412 [Medline] [Order article via Infotrieve]
  21. Dikic, I., Batzer, A. G., Blaikie, P., Obermeier, A., Ullrich, A., Schlessinger, J., and Margolis, B. (1995) J. Biol. Chem. 270, 15125-15129 [Abstract/Free Full Text]
  22. Hanks, S. K., Quinn, A. M., and Hunter, T. (1988) Science 241, 42-52 [Medline] [Order article via Infotrieve]
  23. Hanks, S. K., and Quinn, A. M. (1991) Methods Enzymol. 200, 38-62 [Medline] [Order article via Infotrieve]
  24. Krolewski, J. J., Lee, R., Eddy, R., Shows, T. B., and Dalla-Favera, R. (1990) Oncogene 5, 277-282 [Medline] [Order article via Infotrieve]
  25. Martin-Zanca, D., Oskam, R., Mitra, G., Copeland, T., and Barbacid, M. (1989) Mol. Cell. Biol. 9, 24-33 [Medline] [Order article via Infotrieve]
  26. Masiakowski, P., and Caroll, R. D. (1992) J. Biol. Chem. 267, 26181-26190 [Abstract/Free Full Text]
  27. Lamballe, F., Klein, R., and Barbacid, M. (1991) Cell 66, 1-20 [Medline] [Order article via Infotrieve]
  28. Debant, A., Clauser, E., Ponzio, G., Filloux, C., Auzan, C., Contreres, J.-O., and Rossi, B. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 8032-8036 [Abstract]
  29. Ellis, L., Clauser, E., Morgan, D. O., Edery, M., Roth, R. A., and Rutter, W. J. (1986) Cell 45, 721-732 [Medline] [Order article via Infotrieve]
  30. Grønborg, M., Wulff, B. S., Rasmussen, J. S., Kjeldsen, T., and Gammeltoft, S. (1993) J. Biol. Chem. 268, 23435-23440 [Abstract/Free Full Text]
  31. Kato, H., Faria, T. N., Stannard, B., Roberts, J., Charles, T., and LeRoith, D. (1994) Mol. Endocrinol. 8, 40-50 [Abstract]
  32. King, M. J., Sharma, R. P., and Sale, G. J. (1991) Biochem. J. 275, 413-418 [Medline] [Order article via Infotrieve]
  33. Komada, M., and Kitamura, N. (1994) J. Biol. Chem. 269, 16131-16136 [Abstract/Free Full Text]
  34. Longati, P., Bardelli, A., Ponzetto, C., Naldini, L., and Comoglio, P. M. (1994) Oncogene 9, 49-57 [Medline] [Order article via Infotrieve]
  35. Zhang, B., Tavaré, J. M., Ellis, L., and Roth, R. A. (1991) J. Biol. Chem. 266, 990-996 [Abstract/Free Full Text]
  36. Tavaré, J. M., and Siddle, K. (1993) Biochim. Biophys. Acta 1178, 21-39 [Medline] [Order article via Infotrieve]
  37. Hubbard, S. R., Wei, L., Ellis, L., and Hendrickson, W. A. (1994) Nature 372, 746-754 [CrossRef][Medline] [Order article via Infotrieve]
  38. Wilden, P. A., Siddle, K., Haring, E., Backer, J. M., White, M. F., and Kahn, C. R. (1992) J. Biol. Chem. 267, 13719-13727 [Abstract/Free Full Text]
  39. Wilden, P. A., Kahn, C. R., Siddle, K., and White, M. F. (1992) J. Biol. Chem. 267, 16660-16668 [Abstract/Free Full Text]
  40. Feener, E. P., Backer, J. M., King, G. L., Wilden, P. A., Sun, X. J., Kahn, C. R., and White, M. F. (1993) J. Biol. Chem. 268, 11256-11264 [Abstract/Free Full Text]
  41. Wilden, P. A., Backer, J. M., Kahn, C. R., Cahill, D. A., Schroeder, G. J., and White, M. F. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 3358-3362 [Abstract]
  42. Stannard, B., Blakesley, V., Kato, H., Roberts, J., Charles, T., and LeRoith, D. (1995) Endocrinology 136, 4918-4924 [Abstract]
  43. Ouwens, D. M., van der Zon, G. C. M., Pronk, G. J., Bos, J. L., Möller, W., Cheatham, B., Kahn, C. R., and Maassen, J. A. (1994) J. Biol. Chem. 269, 33116-33122 [Abstract/Free Full Text]
  44. Li, S., Ferber, A., Miura, M., and Baserga, R. (1994) J. Biol. Chem. 269, 32558-32564 [Abstract/Free Full Text]
  45. Hernández-Sánchez, C., Blakesley, V., Kalebic, T., Helman, L., and LeRoith, D. (1995) J. Biol. Chem. 270, 29176-29181 [Abstract/Free Full Text]
  46. Mann, R., Mulligan, R. C., and Baltimore, D. (1983) Cell 33, 153-159 [Medline] [Order article via Infotrieve]
  47. Greene, L. A., Cunningham, M. E., Farinelli, S. E., and Park, D. S. (1997) in Culturing Nerve Cells (Banker, G., and Goslin, K., eds), MIT Press, Cambridge, MA
  48. Loeb, D. M., Tsao, H., Cobb, M. H., and Greene, L. A. (1992) Neuron 9, 1053-1065 [Medline] [Order article via Infotrieve]
  49. Peng, X., Greene, L. A., Kaplan, D. R., and Stephens, R. M. (1995) Neuron 15, 395-406 [Medline] [Order article via Infotrieve]
  50. Soltoff, S. P., Rabin, S. L., Cantley, L. C., and Kaplan, D. R. (1992) J. Biol. Chem. 267, 17472-17477 [Abstract/Free Full Text]
  51. Rabin, S. J., Cleghton, V., and Kaplan, D. R. (1993) Mol. Cell. Biol. 13, 2203-2213 [Abstract]
  52. Loeb, D. M., and Greene, L. A. (1993) J. Neorusci. 13, 2919-2929
  53. Batistatou, A., Volonté, C., and Greene, L. A. (1992) Mol. Biol. Cell 3, 363-371 [Abstract]
  54. Miller, A. D., and Rosman, G. J. (1989) BioTechniques 7, 980-990 [Medline] [Order article via Infotrieve]
  55. Hempstead, B. L., Rabin, S. J., Kaplan, L., Reid, S., Parada, L. F., and Kaplan, D. R. (1992) Neuron 9, 883-896 [Medline] [Order article via Infotrieve]
  56. Ohmichi, M., Matuoka, K., Takenawa, T., and Saltiel, A. R. (1994) J. Biol. Chem. 269, 1143-1148 [Abstract/Free Full Text]
  57. Basu, T., Warne, P. H., and Downward, J. (1994) Oncogene 9, 3483-3491 [Medline] [Order article via Infotrieve]
  58. Tsao, H., Aletta, J. M., and Greene, L. A. (1990) J. Biol. Chem. 265, 15471-15480 [Abstract/Free Full Text]
  59. Boulton, T. G., Nye, S. H., Robbins, D. J., Ip, N. Y., Radziejewska, E., Morgenbesser, S. D., DePinho, R. A., Panayotatos, N., Cobb, M. H., and Yancopoulos, G. D. (1991) Cell 65, 663-675 [Medline] [Order article via Infotrieve]
  60. Obermeier, A., Lammers, R., Wiesmüller, K.-H., Jung, G., Schlessinger, J., and Ullrich, A. (1993) J. Biol. Chem. 268, 22963-22966 [Abstract/Free Full Text]
  61. Cowley, S., Paterson, H., Kemp, P., and Marshall, C. J. (1994) Cell 77, 841-852 [Medline] [Order article via Infotrieve]
  62. Traverse, S., Seedorf, K., Paterson, H., Marshall, C. J., Cohen, P., and Ullrich, A. (1994) Curr. Biol. 4, 694-701 [Medline] [Order article via Infotrieve]
  63. Pang, L., Sawada, T., Decker, S. J., and Saltiel, A. R. (1995) J. Biol. Chem. 270, 13585-13588 [Abstract/Free Full Text]
  64. Dikic, I., Schlessinger, J., and Lax, I. (1994) Curr. Biol. 4, 702-708 [Medline] [Order article via Infotrieve]
  65. Qui, M.-S., and Green, S. H. (1992) Neuron 9, 705-717 [Medline] [Order article via Infotrieve]
  66. Traverse, S., Gomez, N., Paterson, H., Marshall, C., and Cohen, P. (1992) Biochem. J. 288, 351-355 [Medline] [Order article via Infotrieve]
  67. Peng, X., Angelastro, J. M., and Greene, L. A. (1996) J. Neurochem. 66, 1191-1197 [Medline] [Order article via Infotrieve]
  68. Herschman, H. R. (1991) Annu. Rev. Biochem. 60, 281-319 [CrossRef][Medline] [Order article via Infotrieve]
  69. Greenberg, M. E., Greene, L. A., and Ziff, E. B. (1985) J. Biol. Chem. 260, 14101-14110 [Abstract/Free Full Text]
  70. Baxter, R. M., Cohen, P., Obermeier, A., Ullrich, A., Downes, C. P., and Doza, Y. N. (1995) Eur. J. Biochem. 234, 84-91 [Abstract]
  71. Kimura, K., Hattori, S., Kabuyama, Y., Shizawa, Y., Takayanagi, J., Nakamura, S., Toki, S., Matsuda, Y., Onodera, K., and Fukui, Y. (1994) J. Biol. Chem. 269, 18961-18967 [Abstract/Free Full Text]
  72. Yao, R., and Cooper, G. M. (1995) Science 267, 2003-2006 [Medline] [Order article via Infotrieve]
  73. Obermeier, A., Bradshaw, R. A., Seedorf, K., Choidas, A., Schlessinger, J., and Ullrich, A. (1994) EMBO J. 13, 1585-1590 [Abstract]
  74. Wei, L., Hubbard, S. R., Hendrickson, W. A., and Ellis, L. (1995) J. Biol. Chem. 270, 8122-8130 [Abstract/Free Full Text]
  75. White, M. F., Shoelson, S. E., Keutmann, H., and Kahn, C. R. (1988) J. Biol. Chem. 263, 2969-2980 [Abstract/Free Full Text]
  76. Yu, K.-T., and Czech, M. P. (1984) J. Biol. Chem. 259, 5277-5286 [Abstract/Free Full Text]
  77. Rosen, O. M., Herrera, R., Olowe, Y., Petruzzelli, L. M., and Cobb, M. H. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 3237-3240 [Abstract]
  78. Herrera, R., and Rosen, O. M. (1986) J. Biol. Chem. 261, 11980-11985 [Abstract/Free Full Text]
  79. Weinmaster, G., Zoller, M. J., Smith, M., Hinze, E., and Pawson, T. (1984) Cell 37, 559-568 [Medline] [Order article via Infotrieve]
  80. Guiton, M., Gunn-Moore, F. J., and Tavaré, J. M. (1995) Biochem. Soc. Trans. 23, 176S [Medline] [Order article via Infotrieve]
  81. Guiton, M., Gunn-Moore, F. J., Stitt, T. N., Yancopoulos, G. D., and Tavaré, J. M. (1994) J. Biol. Chem. 269, 30370-30377 [Abstract/Free Full Text]
  82. Obermeier, A., Bradshaw, R. A., Seedorf, K., Choidas, A., Schlessinger, J., and Ullrich, A. (1995) Ann. N. Y. Acad. Sci. 766, 1-17 [Medline] [Order article via Infotrieve]
  83. Pelicci, G., Lanfrancone, L., Grignani, F., McGlade, J., Cavallo, F., Forni, G., Nicoletti, I., Grignani, F., Pawson, T., and Pelicci, P. G. (1992) Cell 70, 93-104 [Medline] [Order article via Infotrieve]
  84. Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., and Downward, J. (1994) Nature 370, 527-532 [CrossRef][Medline] [Order article via Infotrieve]
  85. Rameh, L. E., Chen, C.-S., and Cantley, L. C. (1995) Cell 83, 821-830 [Medline] [Order article via Infotrieve]
  86. Maddux, B. A., and Goldfine, I. A. (1991) J. Biol. Chem. 266, 6731-6736 [Abstract/Free Full Text]
  87. Baron, V., Gautier, N., Komoriya, A., Hainaut, P., Scimeca, J.-C., Mervic, M., Lavielle, S., Dolais-Kitabgi, J., and Van Obberghen, E. (1990) Biochemistry 29, 4634-4641 [Medline] [Order article via Infotrieve]
  88. Baron, V., Kaliman, P., Gautier, N., and Van Obberghen, E. (1992) J. Biol. Chem. 267, 23290-23294 [Abstract/Free Full Text]
  89. McDonald, N. Q., Murray-Rust, J., and Blundell, T. L. (1995) Structure 3, 1-6 [Medline] [Order article via Infotrieve]
  90. Johnson, L. N., Noble, M. E. M., and Owen, D. J. (1996) Cell 85, 149-158 [Medline] [Order article via Infotrieve]
  91. Tavaré, J. M, and Dickens, M. (1991) Biochem. J. 274, 173-179 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.